The success of combination antiretroviral therapy (cART) has remarkably reduced HIV/AIDS-70 related morbidity and mortality [1] . However, the emergence of antiretroviral (ARV) drug 71 resistance can compromise global HIV/AIDS treatment and prevention strategies [2, 3] . With the 72 increasing use of ARV drugs, HIV drug resistance (HIVDR) surveillance is warranted. Among 73 other ARV drugs, integrase strand transfer inhibitors (INTSIs) are increasingly prescribed 74 because of their tolerability and efficacy [4] [5] [6] . In particular, raltegravir (RAL), elvitegravir 75 (EVG), dolutegravir (DTG), and bictegravir (BIC), are currently in clinical use [7] , with 76 cabotegravir (CAB) in advanced clinical development [8] . However, similar to other ARV drugs, 77 emerging INSTI resistance may become a barrier to HIV disease management [9] . 78 HIV drug resistance can be inferred via automated sequence-based genotyping, with 79 interpretations of nucleic acids driven at least in part, by genotype-phenotype correlations. 80
Genotyping is usually preferred over quantitative phenotyping for routine clinical testing because 81 of lower costs, faster turn-around time, and greater accessibility [10] . However, phenotyping can 82 provide insight required for adequate understanding of ARV drug resistance. Most importantly, it 83 has been challenging to understand INSTI resistance because: a) phenotypic resistance data is 84 relatively sparse for INSTIs; b) there are low reported failure rates of patients on INSTIs; c) in 85 vitro drug resistance selection has been slow or unsuccessful [11] ; and d) multiple mutations may 86 be required to confer resistance [12] . 87
While in vitro INSTI drug selection experiments, typically starting from clonal HIV 88 subtype B isolates, have been instrumental in providing detailed insights to the emergence of 89 novel HIVDR mutations [13] ; these cannot represent the majority of virus sequence diversity 90 observed in vivo. In order to capture the breadth of the naturally occurring viral variation in 91 INSTI-naïve and experienced populations, it is essential to generate patient-derived integrase 92 isolates and perform in vitro phenotyping. Therefore, in this study, we performed a relatively 93 large-scale phenotypic analysis of HIV drug resistance in clinically-derived isolates, focusing on 94 all five INSTIs to maximize coverage of in vivo sequence variation. 95
MATERIALS AND METHODS 96

Research ethics approval 97
The University of British Columbia Providence Health Care Research Ethics Board 98 approved this research study (protocol H14-03423) . 99
Selection of clinical samples 100
The materials and methods employed in this study were previously reported [12] . The 101
British Columbia Centre for Excellence in HIV/AIDS (BCCfE) routinely conducts clinical HIV 102 genotypic drug resistance testing on total nucleic acid extracts (RNA/DNA) derived from patient 103 plasma samples, and the DNA sequence data is regularly uploaded to the BCCfE's secure Oracle 104 database. For the purposes of this study, clinical samples with integrase genotypic resistance 105 tests and their DNA sequences were identified from the BCCfE database (N= 17,197) . A total of 106 27 amino acid positions in integrase were identified as having amino acids that differed in 107 prevalence between INSTI-treated (primarily RAL and/or EVG) and naïve individuals, 108 (https://hivdb.stanford.edu/cgi-bin/MutPrevBySubtypeRx.cgi) at the time of study design. Of the 109 27 amino acid positions, (51, 66, 68, 74, 92, 95, 97, 114, 118, 121, 128,138, 140, 143, 145, 146, 110 147, 148, 151, 153, 155, 157, 163, 230 and 263) , 25 have been previously reported and are part 111 of the Standard HIVdb ver. 8.4 interpretive algorithm for integrase (Supplemental Figure 1) 
Recombinant virus production 150
Linearized pNL4.3∆int was generated using BstEII restriction digestion as previously 151 described [16] . Recombinant viruses were generated by co-transfecting linearized pNL4.3∆int 152 with the corresponding second round PCR product into CEM-GXR cells, via electroporation 153 using a Bio-Rad GenePulser II. Transfected cells were transferred into tissue culture flasks with 154 5 mL of room temperature Roswell Park Memorial Institute (RPMI) culture medium 155 supplemented with 20% fetal bovine serum (R20+) and incubated at 37 °C in a humidified 5% 156 CO2 atmosphere. After co-transfection, 2 mL of fresh R20+ was added every two to three days 157 until the total volume of each tissue culture flask reached 10 mL. After which, 2 mL of 158 supernatant was removed and replenished with fresh R20+ media until harvest. Green 159 fluorescent protein (GFP) expression was monitored by flow cytometry (FACSCalibur Guava 160 8HT [Millipore]) starting on day 12, as previously described [16] . Once the infection (GFP-161 positive cells) reached 15-30%, viruses were harvested and stored at -80C until use. HIV-1 162 RNA was extracted from the harvested viruses and subjected to nested RT-PCR and Sanger 163 sequencing of integrase, as described previously [12, 17] . The harvested recombinant virus 164 sequences were confirmed to be identical to the amplicon sequences at 27 codon positions. 165
Recombinant viruses with a unique permutation of amino acids at the 27 positions of interest 166 were assayed for phenotypic drug resistance. For viruses, which were identical at the 27 167 positions of interest, only a single virus (chosen arbitrarily) was assayed. 168
Phenotypic drug susceptibility assays 169
Recombinant virus titres were determined by infecting MT4-LTR-EGFP cells in a three-170 day assay and infectivity data collected using a SpectraMax i3 Minimax 300 microplate reader 171 and cytometer (Molecular Devices, San Jose, USA). The SpectraMax captures images of each 172 individual well of a 96-well plate and counts the number of infected (GFP-positive cells) and 173
non-infected (GFP-negative) cells. Titered volumes of recombinant viruses (such that 15% -30% 174
infection is reached on the third or fourth day post-infection) and MT4-LTR-EGFP cells were 175 plated in triplicate with eight concentrations ranging from no drug to 1000nM (10-fold dilutions 176 from 0.1nM to 1000nM with 3nM and 45nM included) of BIC, CAB, DTG, RAL, and EVG. 177 Viral infectivity data was measured using the SpectraMax microplate reader 178
Data analysis and graphing 179
Graphs and statistical analysis were done in R (version 3.2.3). The 50% effective 180 concentrations (EC50s) were calculated by fitting to a four parameter EC50 model using in-181 house scripts written in R using the nplr package version 0.1-7. Fold changes (FC) in EC50 of 182 the virus relative to a NL4.3 control virus were calculated using mean EC50s (performed in 183 triplicate). Fold change values were log transformed and presented as log-FC. 184
185
RESULTS
186
Systematic determination of amino acid permutations to test in vitro 187
To maximize the efficiency of HIV integrase phenotyping, we implemented a systematic 188 approach to identify clinical samples capturing the most commonly occurring amino acid 189 permutations at 27 positions in integrase associated with INSTI exposure in vivo. A total of 288 190 amino acid permutations at these positions were observed in our large clinical database 191 (Supplemental Table 1 Table 3 . 212
We observed a wider log-FC shift for subtype B compared to non-B viruses (Figure 2) . Among 213 single variants, R263K was the only single variant conferring >3-FC for all DTG, BIC and CAB 214 (3.9, 3.2 and 4-fold, respectively). The single mutants N155H, E157Q and Y143R had >3-FC for 215 RAL and EVG. Among the double mutants observed, T66I/G118R had >3-FC for DTG, BIC and 216 CAB. G140S/Q148R showed consistently >3-FC for all five drugs. N155H/G163E had >3-FC 217 for CAB (and RAL and EVG) but was susceptible to DTG and BIC. R263K/G163E had 218 consistently higher FC (>3-FC) as a double mutant as well. E138K/Q148R had >10 and >200-FC 219 for RAL and EVG, respectively. Among triple mutants observed, E138A/G140S/Q148H showed 220 >5-FC for CAB, however it was susceptible to BIC and DTG (2 and 2.8-FC, respectively). As 221 shown previously [12] , eight viruses carried G140S/Q148H only, two had the combination 222 G140S/Q148H + T97A and 3 viruses had G140S/Q148H + T97A + L74M. Viruses with 223 G140S/Q148H were highly resistant to RAL and EVG with >100-FC but had relatively small 224 changes in susceptibility to DTG, BIC and CAB (median 2.9 to 4.7 FC). Viruses with an 225 additional T97A substitution or additional T97A + L74M substitutions maintained high FC to 226 RAL and EVG (>100-FC) but were increasingly resistant to DTG, BIC, and CAB [12] . Among 227 quadruple mutants, V79I/E138K/G140A/Q148R had >10-FC for DTG, BIC and CAB. A virus 228 carrying six amino acid substitutions (L74I/V79I/G140A/Q148R/V151I/ E157Q) showed high 229 FC to DTG, BIC and CAB (>500-FC). One additional virus carrying six amino acid substitutions 230 (L74I/T97M/F121C/V151I/E157Q/G163K) showed >50-FC for CAB, however it was 231 susceptible to DTG and BIC. The greatest exceptions were variants with N155H/G163E or 232 L74I/T97M/F121C/V151I/E157Q/G163K, where both had >75-FC for CAB, while <3-FC for 233
DTG and BIC (Figure 3). 234
Extensive cross-resistance between DTG, BIC and CAB 235
Spearman rank correlation coefficients of log-FC values between DTG and BIC or CAB were 236 strongly correlated, with BIC and CAB with correlation coefficients of 0.93 (slope 0.81) and 237 0.87 (slope 1.1), respectively ( Figure 4A, 4B Systematically screening large panels of clinically-derived isolates from patients offers insights 249 into resistance phenotypes conferred by integrase variation and can inform genotypic resistance 250 interpretation algorithms, such as the Stanford HIVdb [15] . 251
The rationale behind our systematic screening strategy is worth the discussion here L74M/T97A/G140S/Q148H. Moreover, there is no data on BIC and CAB other than our report 278 here and some recent conference proceedings [20] [21] [22] . 279
In addition, two variants containing G140S/Q148R showed modest FC values for DTG (4 280 and 6.2) [23, 24] . This is similar to our reported FC values of 3.7 and 4.9. There have been 281 reports on laboratory-adapted strains that carry Q148R/N155H with DTG FC of about 5, but we 282 have not observed a N155H mutation co-exist with a 148R in over 15,000 clinical isolates. Most 283 commonly, N155H and Q148K exist in combination with G140S in our database. This suggests 284 the difficulty of creating laboratory generated strains using site-directed mutagenesis that 285 accurately represent the in vivo sequence observed in clinically-derived samples. In addition, we 286
have not yet observed a variant carrying E138K/S147G/N155H/T97A/V151I, previously 287 reported to be highly resistant to DTG (>50-FC) [25] . 288
Consistent with previous reports, we observed that for the first-generation INSTIs RAL 289 and EVG, higher log-FC values (exceeding limits of our analysis) for viruses carrying G140S 290 and Q148H. However, these viruses were still susceptible to second-generation INSTIs DTG, 291 BIC and an investigational drug, CAB. The addition of one or more substitutions (T97A and 292 L74M) conferred greater resistance to DTG, BIC and CAB. Results were concordant with 293 previously published data and confirmed extensive cross-resistance between DTG, BIC and CAB 294 [12] . 295
Some limitations of the study merit mention here. First, this study reflects populations 296 either primarily exposed to RAL/EVG, or with no known prior exposure to INSTIs and as such, 297 the >15,000 sequences considered here does not capture all sequence variation likely to be 298 observed in patients failing second-line INSTI. Second, our focus on 27 amino acid substitutions 299 only within the integrase gene may omit the contributions of other substitutions inside the 300 integrase gene in conferring resistance, so we cannot make causal conclusions between the 301 observed phenotypes and genotypes. Moreover, we have not looked at amino acid substitutions 302 outside integrase which may confer low, medium and/or high-level resistance to the current 303 Table 3. This table lists Table 1 ) later in the study, which increased the total number to 15,285 samples. The latter number was used to perform coverage analysis presented here.
